.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Randomized trials of urate-lowering therapy in asymptomatic hyperuricemia have produced important cautionary evidence for clinicians. The FEATHER trial, for example, tested febuxostat in patients with stage 3 chronic kidney disease and asymptomatic hyperuricemia and did not show a significant overall benefit on kidney function decline compared with placebo. These findings are relevant because elevated serum uric acid is common in CKD and can easily become a therapeutic target by association rather than by proven outcome benefit. For internists, treatment decisions should distinguish asymptomatic hyperuricemia from established gout, urate nephrolithiasis or other clear indications for therapy. Kidney disease should be managed according to evidence-based nephroprotective strategies rather than assuming that urate reduction will automatically change its course. The study also illustrates why intermediate biochemical improvements should not be equated with hard clinical benefit. A practical approach is to define the indication for urate-lowering therapy clearly, consider the patient's comorbidities and medication profile, and revisit the evidence rather than treating a laboratory abnormality in isolation.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Randomized trials of urate-lowering therapy in asymptomatic hyperuricemia have produced important cautionary evidence for clinicians. The FEATHER trial, for example, tested febuxostat in patients with stage 3 chronic kidney disease and asymptomatic hyperuricemia and did not show a significant overall benefit on kidney function decline compared with placebo. These findings are relevant because elevated serum uric acid is common in CKD and can easily become a therapeutic target by association rather than by proven outcome benefit. For internists, treatment decisions should distinguish asymptomatic hyperuricemia from established gout, urate nephrolithiasis or other clear indications for therapy. Kidney disease should be managed according to evidence-based nephroprotective strategies rather than assuming that urate reduction will automatically change its course. The study also illustrates why intermediate biochemical improvements should not be equated with hard clinical benefit. A practical approach is to define the indication for urate-lowering therapy clearly, consider the patient's comorbidities and medication profile, and revisit the evidence rather than treating a laboratory abnormality in isolation.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
2 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
3 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
3 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
3 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
3 days back
